UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate

Journal of clinical pharmacology, 2021-01, Vol.61 (1), p.90-104

2021

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I

Clinical pharmacokinetics, 2019-01, Vol.58 (1), p.101-113

2019

Volltextzugriff (PDF)

A drug‐disease model for predicting survival in an Ebola outbreak

Clinical and translational science, 2022-10, Vol.15 (10), p.2538-2550

2022

Volltextzugriff (PDF)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

Journal of pharmacokinetics and pharmacodynamics, 2021-08, Vol.48 (4), p.479-494

2021

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects

Clinical pharmacology in drug development, 2020-08, Vol.9 (6), p.742-755

2020

Volltextzugriff (PDF)

Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-N-acetic Acid (Lidorestat) and Congeners as Highly Potent and Selective Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications

Journal of medicinal chemistry, 2005-05, Vol.48 (9), p.3141-3152

2005

Volltextzugriff (PDF)

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

Clinical and translational science, 2022-04, Vol.15 (4), p.954-966

2022

Volltextzugriff (PDF)

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

Journal of the American Heart Association, 2016-06, Vol.5 (6), p.n/a

2016

Volltextzugriff (PDF)

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis

CPT: pharmacometrics and systems pharmacology, 2020-07, Vol.9 (7), p.405-416

2020

Volltextzugriff (PDF)

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

The New England journal of medicine, 2021-09, Vol.385 (13), p.1184-1195

2021

Volltextzugriff (PDF)

Evaluation of Potential Disease‐Mediated Drug–Drug Interaction in Patients With Moderate‐to‐Severe Atopic Dermatitis Receiving Dupilumab

Clinical pharmacology and therapeutics, 2018-12, Vol.104 (6), p.1146-1154

2018

Volltextzugriff (PDF)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

The Journal of infectious diseases, 2022-12, Vol.227 (1), p.23-34

2022

Volltextzugriff (PDF)

Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial

Clinical infectious diseases, 2022-08, Vol.75 (1), p.e380-e388

2022

Volltextzugriff (PDF)

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-03, Vol.22 (6), p.1348-1355

2016

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations

Journal of clinical lipidology, 2019-11, Vol.13 (6), p.970-978

2019

Volltextzugriff (PDF)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data

Clinical pharmacology in drug development, 2021-11, Vol.10 (11), p.1345-1357

2021

Volltextzugriff (PDF)

REGEN-COV ® antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification

Bioanalysis, 2021-12, Vol.13 (24), p.1827-1836

2021

Volltextzugriff (PDF)

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

Journal of clinical lipidology, 2019-11, Vol.13 (6), p.979-988.e10

2019

Volltextzugriff (PDF)

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial

Journal of clinical lipidology, 2020-09, Vol.14 (5), p.707-719

2020

Volltextzugriff (PDF)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data

Clinical pharmacology in drug development, 2020-08, Vol.9 (6), p.756-767

2020

Volltextzugriff (PDF)

Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases

BMJ open ophthalmology, 2019-01, Vol.4 (1), p.e000185-e000185

2019

Volltextzugriff (PDF)

The use of a high-throughput luminescent method to assess CYP3A enzyme induction in cultured rat hepatocytes

In vitro cellular & developmental biology. Animal, 2008-05, Vol.44 (5), p.129-134

2008

Volltextzugriff (PDF)

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Blood, 2022-11, Vol.140 (Supplement 1), p.11912-11913

2022

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(47)
Dissertationen
(1)

Sprache

Englisch
(48)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Humans
(24)
Monoclonal Antibodies
(17)
Female
(14)
Pharmacokinetics
(14)
Adult
(13)
Middle Aged
(12)
Pharmacology & Pharmacy
(12)
Male
(11)
Aged
(9)
Covid-19
(7)
Drug Dosages
(7)
Pharmacodynamics
(7)
Animals
(6)
Coronaviruses
(6)
Double-Blind Method
(6)
Severe Acute Respiratory Syndrome Coronavirus 2
(6)
Antibodies, Monoclonal, Humanized - Pharmacokinetics
(5)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I

A drug‐disease model for predicting survival in an Ebola outbreak

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects

Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-N-acetic Acid (Lidorestat) and Congeners as Highly Potent and Selective Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Evaluation of Potential Disease‐Mediated Drug–Drug Interaction in Patients With Moderate‐to‐Severe Atopic Dermatitis Receiving Dupilumab

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data

REGEN-COV ® antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification

COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: Subgroup analysis in participants with cardiovascular disease and diabetes

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data

Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases

The use of a high-throughput luminescent method to assess CYP3A enzyme induction in cultured rat hepatocytes

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Suchergebnisse filtern